After 11 years in pharma commercial strategy, I’ve seen the same scene play out every Q1: Leadership worldpharmatoday.com teams gather to decide on the annual conference spend. The conversation usually starts with, "We have to be at ASCO, obviously," and devolves into a game of FOMO (Fear Of Missing Out) where the budget is cannibalized by five-star dinners and flashy booth designs that serve no real strategic purpose.
If you are in Medical Affairs, your attendance at a congress is an investment of time, human capital, and focus. If you can’t draw a direct line between your presence and a specific shift in your scientific narrative or KOL engagement strategy, you shouldn’t be there. Let’s break down how to actually plan your congress year.
The Congress Selection Audit: Outcomes Over Optics
The biggest mistake in building a medical affairs congress plan is treating every meeting as an opportunity for "general visibility." Visibility doesn't drive adoption. Specific, high-intent conversations do. Before you clear your calendar for a major meeting, subject it to the "Triple-Constraint Test":
- The Narrative Test: Does this conference allow us to evolve our scientific narrative with our core target audience? The Engagement Test: Are we aiming for a high-volume "meet and greet," or are we looking for deep-dive, two-way dialogue with high-impact KOLs? The Outcome Test: Can we track a tangible change in data perception or referral behavior because of this interaction?
The Scientific Anchors: AACR and ASCO
Here's what kills me: for oncology teams, aacr and asco are the bookends of the year. However, their utility is fundamentally different. If you treat them as the same type of meeting, you are wasting your team's bandwidth.
AACR (American Association for Cancer Research) is where you stress-test the science. Your focus here should be on early-stage data, platform validation, and engaging with the researchers who are actually driving the discovery engine. If you are there to "talk commercial," you are in the wrong room.
ASCO (American Society of Clinical Oncology) is where clinical practice changes. The noise is immense. Your medical affairs teams shouldn't be wandering the halls looking for "buzz." They should be executing a targeted plan of 1:1 engagement that synthesizes how your data fits into the rapidly evolving standard of care. If your team is spending more time at the booth than in private meetings or scientific sessions, you are missing the point.
Beyond the Oncology Stage: A Strategic Portfolio
A smart medical affairs strategy realizes that oncology clinicians don't exist in a vacuum. You need to leverage other venues to understand the business and access realities that impact whether your medicine ever actually reaches a patient.
Conference/Platform Primary Strategic Goal KPI for Medical Affairs BIO Partnering Licensing & Pipeline Strategy Number of high-value pipeline conversations vs. just "showing the deck." Fierce Pharma Week Commercial Execution & CI Quality of insights regarding market competitor positioning and GTM shifts. THMA Forums Formulary Reality & Health Systems Depth of understanding regarding real-world access hurdles for your specific molecule.1. BIO Partnering: The Summer Anchor
Most Medical Affairs teams ignore the BIO Partnering platform. That’s a mistake. While BD handles the contracts, Medical Affairs should be using this platform to understand the competitive landscape three to five years out. Who are the emerging players? What data sets are being built? Use this as an "intelligence anchor" to calibrate your own pipeline communications.
2. Fierce Pharma Week: The Commercial Pulse
You cannot effectively support a brand if you don't understand the pressures on your commercial colleagues. Fierce Pharma Week is less about "new science" and more about how the market is reacting to commercial moves. Use this to sharpen your competitive intelligence—not by spying on competitors, but by understanding how the market receives the messaging you are currently providing.
3. The Health Management Academy (THMA): The Reality Check
If you don't understand how your drug is being formulary-managed at a system level, your scientific narrative is irrelevant. THMA (The Health Management Academy) forums are vital for Medical Affairs because they bring you into the room with health system executives. These people don't care about your latest abstract as much as they care about the burden of illness and the total cost of care. If your Medical Affairs team hasn't participated in these discussions, you are missing the most critical input for your MSL field strategy.
The "Nothing Burger" Checklist: Avoiding Common Traps
I maintain a running list of meetings that look big on a calendar but do nothing for adoption. Before you finalize your travel budget, ask these three questions:
Is the ROI a "Hand-wavy" metric? If the justification is "brand awareness," cut it. We aren't selling soda; we are driving clinical practice change. Are we just "Being Seen"? If your goal is to "keep our logo in front of physicians," remember that physicians are busy. They don't care about your logo. They care about their patient's outcomes. Are we leveraging the meeting, or just attending? If you aren't scheduling at least 10 high-value, 30-minute 1:1 sessions with key stakeholders, the conference is a vacation in disguise.Final Strategy for Your Team
Stop thinking like a marketer and start thinking like a strategist. A high-quality medical affairs congress plan is lean. It’s surgical. It prioritizes the meeting where the clinician is forced to confront your data (ASCO/AACR) and the meeting where the payer is forced to confront the system-wide burden of the disease (THMA).
If you cannot articulate why you are at a meeting in one sentence, skip it. Redirect that budget into field-based 1:1 engagements where the real work happens. The goal isn't to be everywhere—the goal is to be in the room when the decisions that matter to your patient population are actually being made.. Pretty simple.